Targeting Pathways in Polycystic Ovary Syndrome (PCOS) Using Metformin (MET)

Completed · Phase 1

Conditions studied: Polycystic Ovary Syndrome

In brief

The investigator's global hypothesis is that women with Polycystic Ovary Syndrome (PCOS) can be separated into subtypes based on their response to metformin. The investigators propose here to use both targeted and non-targeted metabolomic approach to identify pathways associated with metformin's effect on insulin sensitivity and endothelial function. This pilot project will be the foundation for developing tailored therapeutic approaches to Polycystic Ovary Syndrome and identifying novel drug targets.

Key facts

Study ID

NCT02086526

Run by

Mayo Clinic

People needed

68

Starts

2014-03-01

Expected to finish

2016-11-20

Last updated by the study team

2018-03-19

Who can join

Age: 18 and older, up to 50. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Body mass index (BMI) greater than or equal to 25
• Polycystic Ovary Syndrome criteria of both oligomenorrhea (<9 menses per year) and androgen excess [clinical hirsutism (Ferriman-Gallway score >8 or severe acne) or elevated testosterone].
• Taking no medications for the treatment of insulin resistance.

You may not qualify if…

• Diagnosis of Cushing's syndrome
• Untreated hypo/hyperthyroidism
• Elevated prolactin
• Congenital adrenal hyperplasia
• Renal insufficiency (creatinine > 1.5)
• Diabetes
• Medications that can significantly affect endothelial function
• Pregnancy
• Breast Feeding
• Taking oral contraceptives
• Currently smoking

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.